The United States Food and Drug Administration (FDA) has approved the oral capsule formulation of Eisai’s Aloxi® (palonosetron) for the prevention of chemotherapy-induced nausea and vomiting.
Aloxi is a 5-hydroxytryptamine-3 receptor antagonist approved for preventing acute nausea and vomiting in patients who receive initial and repeated moderately emetogenic chemotherapy.
The new oral formulation is for single 0.5 mg capsules that are administered one hour prior to initiation of chemotherapy.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
